FDA Approves First Oral Therapy for Dermatomyositis in Adults

The FDA approved brepocitinib (Lisraya), the first oral therapy specifically indicated for treating adult dermatomyositis, a rare autoimmune disease. The approval follows positive phase 3 trial results demonstrating significant benefit and safety profile compared to placebo and current treatments.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 27 Aug 2026 and 2 Sep 2026.